

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of HER2-Positive Breast Cancer (Webinar Video Proceedings)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Approximately what proportion of hormone receptor-positive breast cancer cases can be classified as HER2 low by immunohistochemical analysis?
 - a. 3%
 - b. 23%
 - c. 43%
 - d. 63%
2. Updated safety analysis from the HER2CLIMB study evaluating the addition of tucatinib to capecitabine and trastuzumab for patients with advanced HER2-positive breast cancer revealed that which of the following Grade ≥ 3 adverse events was NOT increased with tucatinib?
 - a. Nausea
 - b. Diarrhea
 - c. Anemia
 - d. Headache
3. The second interim analysis from the APHINITY trial investigating the efficacy of adjuvant pertuzumab in combination with chemotherapy and trastuzumab for HER2-positive primary breast cancer supports the addition of pertuzumab for which of the following patient subgroups?
 - a. Patients with node-negative disease, regardless of ER status
 - b. Patients with node-positive disease, regardless of ER status
 - c. Patients with ER-positive disease, regardless of lymph node status
 - d. Patients with ER-negative disease, regardless of lymph node status
4. Approximately what proportion of patients in the Phase III TULIP trial for locally advanced or metastatic breast cancer discontinued treatment with SYD985 because of ocular toxicities?
 - a. 10%
 - b. 20%
 - c. 30%
 - d. 50%